News

Filter

1 to 9 of 35 results

Teva receives subpoenas over Copaxone and Azilect marketing

Teva receives subpoenas over Copaxone and Azilect marketing

11-02-2014

The US Department of Justice is investigating Israel drugmaker Teva Pharmaceutical Industries’ marketing…

AzilectCopaxoneLegalMarkets & MarketingNeurologicalPharmaceuticalTeva Pharmaceutical Industries

Teva gains favorable court ruling in Azilect patent case

Teva gains favorable court ruling in Azilect patent case

24-09-2013

Israel-based Teva Pharmaceutical Industries has gained a favorable ruling in its patent infringement…

AzilectGenericsLegalMylan LaboratoriesNeurologicalNorth AmericaTeva Pharmaceutical Industries

ANN meeting highlights: Novartis' Gilenya, Lundbeck's Azilect, Orion's ODM-101, Biotie's tozadenant

21-03-2013

Among the highlights of the annual meeting of the American Academy of Neurology taking place in San Diego,…

AzilectBiotie TherapiesGilenyaLundbeckNeurologicalNovartisODM-101Orion CorpPharmaceuticalResearchTeva Pharmaceutical Industriestozadenant

Patient share of Teva/Lundbeck's Azilect for Parkinson's continues to grow

01-08-2012

Through examination of US patient-level claims data, that patient share of Azilect (rasagiline) - from…

AzilectLundbeckMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical Industries

Teva gets EU clearance for Cephalon acquisition; negative review on Azilect

14-10-2011

Following US antitrust clearance last week, Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA)…

AzilectCephalonMergers & AcquisitionsNeurologicalPharmaceuticalRegulationTeva Pharmaceutical Industries

Variations in Parkinson's disease treatment among prescribers in France, Germany, Italy, Spain and the UK

02-12-2010

When comparing dopamine agonist use for Parkinson's disease, more frequent use of once-daily formulations…

AzilectBoehringer IngelheimFranceGermanyGlaxoSmithKlineItalyLundbeckMarkets & MarketingMirapexNeurologicalPharmaceuticalRequipTeva Pharmaceutical IndustriesUK

Watson in partnership with Moksha8 for Brazil and Mexico, inc $30M investment; files for generic Azilect

06-10-2010

US specialty and generics drugmaker Watson Pharmaceuticals (NYSE: WPI) has entered an accord with Moksha8,…

AzilectGenericsLicensingMergers & AcquisitionsMoksha8NeurologicalNorth AmericaPharmaceuticalRegulationSouth AmericaTeva Pharmaceutical IndustriesWatson Pharmaceuticals

1 to 9 of 35 results

Back to top